Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Letter to the Editor
  • Published:

The NPM1 wild-type OCI-AML2 and the NPM1-mutated OCI-AML3 cell lines carry DNMT3A mutations

Leukemia volume 26, pages 554–557 (2012)Cite this article

Acute myeloid leukemia (AML) is clinically and molecularly a heterogeneous disease. The less-characterized AML subgroup, accounting for about 50% of cases, is the one usually referred to as AML with normal karyotype (AML-NK), whose molecular characteristics still require to be fully determined. During the past decade, several mutations have been identified in association with AML-NK, and two of them were recognized by the 2008 World Health Organization (WHO) classification as defining provisional entities with characteristic biological and clinical features: AML with mutated nucleophosmin (NPM1)1, 2, 3 and AML with mutated CCAAT/enhancer-binding protein alpha (CEBPA).1

More recently, whole-genome and whole-exome sequencing technologies have been used to further unravel the genomic landscape of AML-NK. Novel mutations so far identified in AML-NK using these approaches include those involving the IDH1, IDH2 and DNMT3A genes,4, 5, 6 and others are expected to be found in the future by sequencing additional AML-NK genomes.

This is a preview of subscription content, access via your institution

Relevant articles

Open Access articles citing this article.

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1

References

  1. Arber DA, Brunning RD, Le Beau MM, Falini B, Vardiman JW, Porwit A et al. Acute myeloid leukaemia with recurrent genetic abnormalities. In: Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H et al. (eds). WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. International Agency for Research on Cancer (IARC): Lyon, France, 2008.

    Google Scholar 

  2. Falini B, Mecucci C, Tiacci E, Alcalay M, Rosati R, Pasqualucci L et al. Cytoplasmic nucleophosmin in acute myelogenous leukemia with a normal karyotype. N Engl J Med 2005; 352: 254–266.

    Article  CAS  PubMed  Google Scholar 

  3. Falini B, Martelli MP, Bolli N, Sportoletti P, Liso A, Tiacci E et al. Acute myeloid leukemia with mutated nucleophosmin (NPM1): is it a distinct entity? Blood 2011; 117: 1109–1120.

    Article  CAS  PubMed  Google Scholar 

  4. Mardis ER, Ding L, Dooling DJ, Larson DE, McLellan MD, Chen K et al. Recurring mutations found by sequencing an acute myeloid leukemia genome. N Engl J Med 2009; 361: 1058–1066.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  5. Ley TJ, Ding L, Walter MJ, McLellan MD, Lamprecht T, Larson DE et al. DNMT3A mutations in acute myeloid leukemia. N Engl J Med 2010; 363: 2424–2433.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  6. Yan XJ, Xu J, Gu ZH, Pan CM, Lu G, Shen Y et al. Exome sequencing identifies somatic mutations of DNA methyltransferase gene DNMT3A in acute monocytic leukemia. Nat Genet 2011; 43: 309–315.

    Article  CAS  PubMed  Google Scholar 

  7. Shannon K, Armstrong SA . Genetics, epigenetics, and leukemia. N Engl J Med 2011; 363: 2460–2461.

    Article  Google Scholar 

  8. Figueroa ME, Lugthart S, Li Y, Erpelinck-Verschueren C, Deng X, Christos PJ et al. DNA methylation signatures identify biologically distinct subtypes in acute myeloid leukemia. Cancer Cell 2010; 17: 13–27.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  9. Shah MY, Licht JD . DNMT3A mutations in acute myeloid leukemia. Nat Genet 2011; 43: 289–290.

    Article  CAS  PubMed  Google Scholar 

  10. Kumar P, Henikoff S, Ng PC . Predicting the effects of coding non-synonymous variants on protein function using the SIFT algorithm. Nat Protoc 2009; 4: 1073–1081.

    Article  CAS  PubMed  Google Scholar 

  11. Adzhubei IA, Schmidt S, Peshkin L, Ramensky VE, Gerasimova A, Bork P et al. A method and server for predicting damaging missense mutations. Nat Methods (2010); 7: 248–249.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  12. Wang C, Curtis JE, Minden MD, McCulloch EA . Expression of a retinoic acid receptor gene in myeloid leukemia cells. Leukemia 1989; 3: 264–269.

    CAS  PubMed  Google Scholar 

  13. Walter MJ, Ding L, Shen D, Shao J, Grillot M, McLellan M et al. Recurrent DNMT3A mutations in patients with myelodysplastic syndromes. Leukemia 2011; 25: 1153–1158.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  14. Quentmeier H, Martelli MP, Dirks WG, Bolli N, Liso A, Macleod RA et al. Cell line OCI/AML3 bears exon-12 NPM gene mutation-A and cytoplasmic expression of nucleophosmin. Leukemia 2005; 19: 1760–1767.

    Article  CAS  PubMed  Google Scholar 

  15. Grisendi S, Mecucci C, Falini B, Pandolfi PP . Nucleophosmin and cancer. Nat Rev Cancer 2006; 6: 493–505.

    Article  CAS  PubMed  Google Scholar 

  16. Swaminathan V, Kishore AH, Febitha KK, Kundu TK . Human histone chaperone nucleophosmin enhances acetylation-dependent chromatin transcription. Mol Cell Biol 2005; 25: 7534–7545.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  17. Wermke M, Thiede C, Kiani A, Ehninger G, Bornhauser M, Platzbecker U . Successful treatment of molecular relapse in NPM1-positive AML using 5-azacytidine. Leukemia 2010; 24: 236–237.

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgements

This study was supported by A.I.R.C. (Associazione Italiana Ricerca sul Cancro).

Author information

Authors and Affiliations

  1. Department of Clinical and Experimental Medicine, Institute of Hematology, University of Perugia, Perugia, Italy

    E Tiacci, A Spanhol-Rosseto, M P Martelli & B Falini

  2. Institute for Cancer Genetics and the Department of Pathology, Columbia University, New York, NY, USA

    L Pasqualucci

  3. DSMZ (Deutsche Sammlung von Mikroorganismen und Zellkulturen,

    H Quentmeier & H G Drexler

  4. German Collection of Microorganisms and Cell Cultures), Braunschweig, Germany

    H Quentmeier & H G Drexler

  5. Munich Leukemia Laboratory (MLL), Munich, Germany

    V Grossmann

Authors
  1. E Tiacci
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. A Spanhol-Rosseto
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. M P Martelli
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. L Pasqualucci
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. H Quentmeier
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. V Grossmann
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. H G Drexler
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. B Falini
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to B Falini.

Ethics declarations

Competing interests

Vera Grossmann is employed by MLL Munich Leukemia Laboratory GmbH.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Tiacci, E., Spanhol-Rosseto, A., Martelli, M. et al. The NPM1 wild-type OCI-AML2 and the NPM1-mutated OCI-AML3 cell lines carry DNMT3A mutations. Leukemia 26, 554–557 (2012). https://doi.org/10.1038/leu.2011.238

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/leu.2011.238

This article is cited by

Search

Advanced search

Quick links